November 22, 2023
2 min watch
Save
VIDEO: Brimochol PF for presbyopia meets endpoints in phase 3 trial
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Julia Williams of Visus Therapeutics discusses positive results from the phase 3 BRIO-I clinical trial investigating Brimochol PF for presbyopia treatment.
“Our BRIO-I results showed that our Brimochol formulation met the primary and secondary endpoints, along with achieving the contribution of elements requirement for a fixed-dosed combination, and was well tolerated,” she said.
The company expects a data redout for the phase 3 BRIO-II trial in the second half of 2024, Williams said.
Published by:
Sources/Disclosures
Collapse
Source:
Bergo B. Visus Therapeutics. Presented at: Eyecelerator@AAO; Nov. 2, 2023; San Francisco.
Disclosures:
Williams reports being vice president of clinical and medical affairs at Visus Therapeutics.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.